Menu
Recruiting NCT06961968

Randomized Withdrawal Study in Patients With Schizophrenia

Phase III Interventional Schizophrenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: iloperidone, placebo.
Who it may be relevant to
Registry conditions: Schizophrenia. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection

Overview

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

Interventions

  • Drug iloperidone
    iloperidone LAI
  • Drug placebo
    matching placebo

Primary outcome measures

  • Time to exacerbation of symptoms [Time frame: Up to 52 weeks post-randomization]

Eligibility criteria

Inclusion criteria

  • Males or females 18 to 65 years of age (inclusive)
  • Diagnosed with schizophrenia per DSM-5 criteria
  • In need of ongoing psychiatric treatment

Exclusion criteria

  • DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

United States · 22 centers
  • Vanda Investigational Site — Rogers
  • Vanda Investigational Site — Costa Mesa
  • Vanda Investigational Site — Lemon Grove
  • Vanda Investigational Site — Oceanside
  • Vanda Investigational Site — Pico Rivera
  • Vanda Investigational Site — San Diego
  • Vanda Investigational Site — Walnut Creek
  • Vanda Investigational Site — North Miami
  • … and 14 more centers

Identifiers

NCT: NCT06961968 · VP-VYV-683-3102

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗